论文部分内容阅读
目的探讨维格列汀对难治性2型糖尿病患者的治疗效果。方法 25例使用多种降糖药物联合治疗血糖仍控制不佳的难治性2型糖尿病患者,完成基线评估后,在原有降糖方案基础上加用维格列汀50 mg b.i.d.共治疗4周,治疗前后均进行空腹血糖(FPG)、餐后2 h血糖(2 h PG)和糖化血红蛋白(HbA1c)的检测。结果治疗前患者平均FPG(13.5±2.7)mmol/L,平均2 h PG为(16.9±1.9)mmol/L,平均HbA1c为(11.5±1.6)%。加用维格列汀治疗4周后,患者FPG及2 h PG均较前显著下降(P<0.05),HbA1c亦有下降的趋势,但差异无统计学意义(P>0.05)。结论维格列汀对难治性2型糖尿病患者具有良好的降糖效果,并且具有良好的安全性。
Objective To investigate the effect of vildagliptin on patients with refractory type 2 diabetes. Methods Twenty-five patients with refractory type 2 diabetes mellitus who were still under the control of blood glucose were treated with various antidiabetic drugs. After completing the baseline assessment, they were treated with vildagliptin 50 mg bid for 4 weeks Before and after treatment, fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h PG) and HbA1c were detected. Results The average pre-treatment FPG was (13.5 ± 2.7) mmol / L, mean PG was (16.9 ± 1.9) mmol / L for 2 h, and mean HbA1c was (11.5 ± 1.6)%. After 4 weeks of treatment with vildagliptin, FPG and 2 h PG were significantly decreased (P <0.05) and HbA1c was also decreased, but the difference was not statistically significant (P> 0.05). Conclusion Vildagliptin has a good hypoglycemic effect on patients with refractory type 2 diabetes mellitus, and has good safety.